Celgene planning regulatory submissions for Revlimid in indolent lymphoma on Phase III win

Celgene Corp. (NASDAQ:CELG) said Revlimid lenalidomide plus Rituxan rituximab met the primary endpoint of improving progression-free survival (PFS) vs. placebo plus Rituxan in the Phase III AUGMENT trial to treat relapsed or refractory follicular and marginal zone lymphoma. The company said it observed a "favorable trend" for overall survival (OS), and follow-up will continue for mature OS data. Data from the double-blind, international trial, which enrolled 358 patients, will be submitted for presentation at a medical meeting.

Celgene plans to submit global regulatory applications in 1Q19 for the indication...